Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nelfinavir Mesylate Clear all
Not listed Phase 3 Interventional

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

NCT00009061
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
37
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 3 Interventional

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

NCT00002224
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Oct 2, 2026, 11:26 AM EDT
Not listed Phase 3 Interventional

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005002
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate
Drug · Biological
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00002380
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Months to 13 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

NCT00001122
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 2, 2026, 11:26 AM EDT
Not listed Not applicable Interventional

Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment

NCT00006591
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Amprenavir
Drug
Lead sponsor
Gathe, Joseph, M.D.
Individual
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

NCT00002185
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

A Study of Viracept in HIV-Positive Women

NCT00002171
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Recruiting Phase 2 Interventional

Autophagy Maintenance (AUTOMAIN)

NCT06971744
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Hydroxychloroquine, Nelfinavir, Bevacizumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 2, 2026, 11:26 AM EDT
Completed No phase listed Observational

A Study of HIV Levels During Pregnancy and After Childbirth

NCT00041964
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

NCT00000941
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 2, 2026, 11:26 AM EDT
Terminated Early Phase 1 Interventional

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

NCT02080416
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Kaposi Sarcoma, Gastric Cancer, Nasopharyngeal Cancer, EBV, Castleman Disease
Interventions
Nelfinavir
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Viracept Expanded Access Program

NCT00002165
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

NCT00233948
View directory record Official record
Conditions
Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
nelfinavir mesylate, biopsy, laboratory biomarker analysis, pharmacological study, gene expression analysis, western blotting, reverse transcriptase-polymerase chain reaction, immunoenzyme technique
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

NCT00017758
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Lipodystrophy
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
10
States / cities
Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2006 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

NCT00002184
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002440
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
16 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • New Haven, Connecticut • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 4 Interventional Results available

Mechanisms of Lipodystrophy in HIV-Infected Pateints

NCT00457665
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir, Efavirenz
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Not applicable Interventional

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

NCT00000892
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Delavirdine mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 2, 2026, 11:26 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor

NCT00385450
View directory record Official record
Conditions
Cardiopulmonary Bypass
Interventions
Nelfinavir/placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Not applicable Interventional

A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

NCT00002216
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir, Nelfinavir mesylate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

A Study of 141W94 in Combination With Other Anti-HIV Drugs

NCT00002372
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Amprenavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

NCT00001091
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Months to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 2, 2026, 11:26 AM EDT